{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T12:30:56Z","timestamp":1781008256299,"version":"3.54.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2016,4,4]],"date-time":"2016-04-04T00:00:00Z","timestamp":1459728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,4,4]],"date-time":"2016-04-04T00:00:00Z","timestamp":1459728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1038\/bmt.2016.79","type":"journal-article","created":{"date-parts":[[2016,4,4]],"date-time":"2016-04-04T13:43:07Z","timestamp":1459777387000},"page":"1032-1040","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma"],"prefix":"10.1038","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3987-419X","authenticated-orcid":false,"given":"M","family":"Martino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R M","family":"Lemoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Girmenia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Castagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Cavallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Offidani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Scortechini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Montanari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7840-4414","authenticated-orcid":false,"given":"G","family":"Milone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Postacchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Olivieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,4]]},"reference":[{"key":"BFbmt201679_CR1","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/j.bbmt.2013.08.002","volume":"19","author":"LJ Costa","year":"2013","unstructured":"Costa LJ, Zhang MJ, Zhong X, Dispenzieri A, Lonial S, Krishnan A et al. Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. Biol Blood Marrow Transplant 2013; 19: 1615\u20131624.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201679_CR2","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/bmt.2014.312","volume":"50","author":"JR Passweg","year":"2015","unstructured":"Passweg JR, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P et al. Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants. Bone Marrow Transplant 2015; 50: 476\u2013482.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201679_CR3","doi-asserted-by":"publisher","first-page":"6063","DOI":"10.1182\/blood-2011-02-297325","volume":"117","author":"M Cavo","year":"2011","unstructured":"Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Blad\u00e9 J et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 2011; 117: 6063\u20136073.","journal-title":"Blood"},{"key":"BFbmt201679_CR4","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.bbmt.2015.03.002","volume":"21","author":"N Shah","year":"2015","unstructured":"Shah N, Callander N, Ganguly S, Gul Z, Hamadani M, Costa L et al. Hematopoietic stem cell transplantation for multiple myeloma: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2015; 21: 1155\u20131166.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201679_CR5","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/nrclinonc.2010.104","volume":"7","author":"S Giralt","year":"2010","unstructured":"Giralt S . 200\u2009mg\/m(2) melphalan-the gold standard for multiple myeloma. Nat Rev Clin Oncol 2010; 7: 490\u2013491.","journal-title":"Nat Rev Clin Oncol"},{"key":"BFbmt201679_CR6","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1517\/13543784.2013.788643","volume":"22","author":"M Martino","year":"2013","unstructured":"Martino M, Olivieri A, Offidani M, Vigna E, Moscato T, Fedele R et al. Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma. Expert Opin Investig Drugs 2013; 22: 619\u2013634.","journal-title":"Expert Opin Investig Drugs"},{"key":"BFbmt201679_CR7","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.bbmt.2015.04.020","volume":"21","author":"Y Beaussant","year":"2015","unstructured":"Beaussant Y, Daguindau E, Pugin A, Mohty M, Avet-Loiseau H, Roos-Weil D et al. Hematopoietic stem cell transplantation in multiple myeloma: a retrospective study of the Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle et de Th\u00e9rapie Cellulaire (SFGM-TC). Biol Blood Marrow Transplant 2015; 21: 1452\u20131459.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201679_CR8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/bmt.2014.255","volume":"50","author":"HW Auner","year":"2015","unstructured":"Auner HW, Szydlo R, Hoek J, Goldschmidt H, Stoppa AM, Morgan GJ et al. Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years. Bone Marrow Transplant 2015; 50: 209\u2013215.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201679_CR9","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.bbmt.2013.04.027","volume":"19","author":"PL McCarthy Jr","year":"2013","unstructured":"McCarthy PL Jr, Hahn T, Hassebroek A, Bredeson C, Gajewski J, Hale G et al. Trends in use of and survival after autologous hematopoietic cell transplantation in North America, 1995-2005: significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age. Biol Blood Marrow Transplant 2013; 19: 1116\u20131123.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201679_CR10","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1517\/14712598.2012.707185","volume":"12","author":"M Martino","year":"2012","unstructured":"Martino M, Montanari M, Bruno B, Console G, Irrera G, Messina G et al. Autologous hematopoietic progenitor cell transplantation for multiple myeloma through an outpatient program. Expert Opin Biol Ther 2012; 12: 1449\u20131462.","journal-title":"Expert Opin Biol Ther"},{"key":"BFbmt201679_CR11","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/sj.bmt.1702534","volume":"26","author":"N Summers","year":"2000","unstructured":"Summers N, Dawe U, Stewart DA . A comparison of inpatient and outpatient ASCT. Bone Marrow Transplant 2000; 26: 389\u2013395.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201679_CR12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1080\/13548506.2015.1054843","volume":"21","author":"OG Cant\u00fa-Rodr\u00edguez","year":"2016","unstructured":"Cant\u00fa-Rodr\u00edguez OG, S\u00e1nchez-C\u00e1rdenas M, Trevi\u00f1o-Montemayor OR, Guti\u00e9rrez-Aguirre CH, Tar\u00edn-Arzaga L, Jaime-P\u00e9rez JC et al. Impact of outpatient non-myeloablative haematopoietic stem cell transplantation in quality of life vs. conventional therapy. Psychol Health Med 2016; 21: 10\u201319.","journal-title":"Psychol Health Med"},{"issue":"4 Suppl 7","key":"BFbmt201679_CR13","first-page":"25","volume":"21","author":"WP Peters","year":"1994","unstructured":"Peters WP, Ross M, Vredenburgh JJ, Hussein A, Rubin P, Dukelow K et al. The use of intensive clinic support to permit outpatient autologous bone marrow transplantation for breast cancer. Semin Oncol 1994; 21 (4 Suppl 7): 25\u201331.","journal-title":"Semin Oncol"},{"key":"BFbmt201679_CR14","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/sj.bmt.1700900","volume":"20","author":"S Jagannath","year":"1997","unstructured":"Jagannath S, Vesole DH, Zhang M, Desikan KR, Copeland N, Jagannath M et al. Feasibility and cost effectiveness of outpatient autotransplants in multiple myeloma. Bone Marrow Transplant 1997; 20: 445\u2013450.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201679_CR15","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/sj.bmt.1701191","volume":"21","author":"BR Meisenberg","year":"1998","unstructured":"Meisenberg BR, Ferran K, Hollenbach K, Brehm T, Jollon J, Piro LD . Reduced charges and costs associated with outpatient autologous stem cell transplantation. Bone Marrow Transplant 1998; 21: 927\u2013932.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201679_CR16","first-page":"1192","volume":"87","author":"F Morabito","year":"2002","unstructured":"Morabito F, Martino M, Stelitano C, Oliva E, Kropp M, Irrera G et al. Feasibility of a mixed inpatient-outpatient model of peripheral blood stem cell transplantation for multiple myeloma. Haematologica 2002; 87: 1192\u20131199.","journal-title":"Haematologica"},{"key":"BFbmt201679_CR17","doi-asserted-by":"publisher","first-page":"4855","DOI":"10.1200\/JCO.2006.06.4238","volume":"24","author":"F Fernandez-Aviles","year":"2006","unstructured":"Fernandez-Aviles F, Carreras E, Urbano-Ispizua A, Rovira M, Mart\u00ednez C, Gaya A et al. Case-control comparison of at-home to total hospital care for autologous stem-cell transplantation for hematologic malignancies. J Clin Oncol 2006; 24: 4855\u20134861.","journal-title":"J Clin Oncol"},{"key":"BFbmt201679_CR18","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/j.1537-2995.2007.01073.x","volume":"47","author":"M Kassar","year":"2007","unstructured":"Kassar M, Medoff E, Seropian S, Cooper DL . Outpatient high-dose melphalan in multiple myeloma patients. Transfusion 2007; 47: 115\u2013119.","journal-title":"Transfusion"},{"key":"BFbmt201679_CR19","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/hon.978","volume":"29","author":"F Ferrara","year":"2011","unstructured":"Ferrara F, Izzo T, Criscuolo C, Riccardi C, Viola A, Delia R et al. Comparison of fixed dose pegfilgrastim and daily filgrastim after autologous stem cell transplantation in patients with multiple myeloma autografted on a outpatient basis. Hematol Oncol 2011; 29: 139\u2013143.","journal-title":"Hematol Oncol"},{"key":"BFbmt201679_CR20","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.4065\/83.10.1131","volume":"83","author":"MA Gertz","year":"2008","unstructured":"Gertz MA, Ansell SM, Dingli D, Dispenzieri A, Buadi FK, Elliott MA et al. Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative. Mayo Clin Proc 2008; 83: 1131\u20131138.","journal-title":"Mayo Clin Proc"},{"key":"BFbmt201679_CR21","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/bmt.2011.126","volume":"47","author":"C Faucher","year":"2012","unstructured":"Faucher C, Le Corroller Soriano AG, Esterni B, Vey N, Stoppa AM, Chabannon C et al. Randomized study of early hospital discharge following autologous blood SCT: medical outcomes and hospital costs. Bone Marrow Transplant 2012; 47: 549\u2013555.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201679_CR22","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.bbmt.2012.12.006","volume":"19","author":"A Holbro","year":"2013","unstructured":"Holbro A, Ahmad I, Cohen S, Roy J, Lachance S, Chagnon M et al. Safety and cost-effectiveness of outpatient autologous stem cell transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant 2013; 19: 547\u2013551.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201679_CR23","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.3109\/10428194.2013.842989","volume":"55","author":"I Scortechini","year":"2014","unstructured":"Scortechini I, Montanari M, Mancini G, Inglese E, Calandrelli M, Chiarucci M et al. Conditioning regimen with BCNU, etoposide, cytarabine and melphalan plus amifostine for outpatient autologous stem cell transplant: feasibility and outcome in 97 patients with lymphoma. Leuk Lymphoma 2014; 55: 1657\u20131660.","journal-title":"Leuk Lymphoma"},{"key":"BFbmt201679_CR24","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.clml.2015.05.006","volume":"15","author":"TM Paul","year":"2015","unstructured":"Paul TM, Liu SV, Chong EA, Luger SM, Porter DL, Schuster SJ et al. Outpatient autologous stem cell transplantation for patients with myeloma. Clin Lymphoma Myeloma Leuk 2015; 15: 536\u2013540.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"BFbmt201679_CR25","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/bmt.2015.46","volume":"50","author":"TM Graff","year":"2015","unstructured":"Graff TM, Singavi AK, Schmidt W, Eastwood D, Drobyski WR, Horowitz M et al. Safety of outpatient autologous hematopoietic cell transplantation for multiple myeloma and lymphoma. Bone Marrow Transplant 2015; 50: 947\u2013953.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201679_CR26","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.bbmt.2014.03.027","volume":"20","author":"M Martino","year":"2014","unstructured":"Martino M, Montanari M, Ferrara F, Ciceri F, Scortechini I, Palmieri S et al. Very low rate of readmission after an early discharge outpatient model for autografting in multiple myeloma patients: an Italian multicenter retrospective study. Biol Blood Marrow Transplant 2014; 20: 1026\u20131032.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201679_CR27","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3109\/10428194.2014.931952","volume":"56","author":"M Martino","year":"2015","unstructured":"Martino M, Russo L, Martinello T, Gallo GA, Fedele R, Moscato T et al. A home-care, early discharge model after autografting in multiple myeloma: results of a three-arm prospective, non-randomized study. Leuk Lymphoma 2015; 56: 801\u2013804.","journal-title":"Leuk Lymphoma"},{"key":"BFbmt201679_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1\u201312.","journal-title":"Control Clin Trials"},{"key":"BFbmt201679_CR29","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood.V93.1.51","volume":"93","author":"DS Siegel","year":"1999","unstructured":"Siegel DS, Desikan KR, Mehta J, Singhal S, Fassas A, Munshi N et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 1999; 93: 51\u201354.","journal-title":"Blood"},{"key":"BFbmt201679_CR30","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1182\/blood.V94.4.1248","volume":"94","author":"A Palumbo","year":"1999","unstructured":"Palumbo A, Triolo S, Argentino C, Bringhen S, Dominietto A, Rus C et al. Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. Blood 1999; 94: 1248\u20131253.","journal-title":"Blood"},{"key":"BFbmt201679_CR31","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1046\/j.1365-2141.2001.02976.x","volume":"114","author":"A Badros","year":"2001","unstructured":"Badros A, Barlogie B, Siegel E, Morris C, Desikan R, Zangari M et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 2001; 114: 600\u2013607.","journal-title":"Br J Haematol"},{"key":"BFbmt201679_CR32","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","volume":"370","author":"T Facon","year":"2007","unstructured":"Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99\u201406): a randomized trial. Lancet 2007; 370: 1209\u20131218.","journal-title":"Lancet"},{"key":"BFbmt201679_CR33","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/ajh.21191","volume":"83","author":"SK Kumar","year":"2008","unstructured":"Kumar SK, Dingli D, Lacy MQ, Benboubker L, Attal M, Buadi FK et al. Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: results from a matched pair analysis. Am J Hematol 2008; 83: 614\u2013617.","journal-title":"Am J Hematol"},{"key":"BFbmt201679_CR34","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1182\/blood-2009-09-241737","volume":"115","author":"A Palumbo","year":"2010","unstructured":"Palumbo A, Bringhen S, Bruno B, Falcone AP, Liberati AM, Grasso M et al. Melphalan 200\u2009mg\/m(2) versus melphalan 100\u2009mg\/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. Blood 2010; 115: 1873\u20131879.","journal-title":"Blood"},{"key":"BFbmt201679_CR35","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3109\/10428194.2011.606942","volume":"53","author":"Q Bashir","year":"2012","unstructured":"Bashir Q, Shah N, Parmar S, Wei W, Rondon G, Weber DM et al. Feasibility of autologous hematopoietic stem cell transplant in patients aged >\/=70 years with multiple myeloma. Leuk Lymphoma 2012; 53: 118\u2013122.","journal-title":"Leuk Lymphoma"},{"key":"BFbmt201679_CR36","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/bmt.2011.82","volume":"47","author":"A Olivieri","year":"2012","unstructured":"Olivieri A, Marchetti M, Lemoli R, Tarella C, Iacone A, Lanza F et al. Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo. Bone Marrow Transplant 2012; 47: 342\u2013351.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201679_CR37","first-page":"329","volume":"83","author":"A Olivieri","year":"1998","unstructured":"Olivieri A, Offidani M, Montanari M, Ciniero L, Cantori I, Ombrosi L et al. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience. Haematologica 1998; 83: 329\u2013337.","journal-title":"Haematologica"},{"key":"BFbmt201679_CR38","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1200\/JCO.2000.18.6.1360","volume":"18","author":"S Siena","year":"2000","unstructured":"Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C . Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000; 18: 1360\u20131377.","journal-title":"J Clin Oncol"},{"key":"BFbmt201679_CR39","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/sj.bmt.1705298","volume":"37","author":"V Pavone","year":"2006","unstructured":"Pavone V, Gaudio F, Console G, Vitolo U, Iacopino P, Guarini A et al. Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. Bone Marrow Transplant 2006; 37: 719\u2013724.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201679_CR40","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/bmt.2008.410","volume":"43","author":"W Bensinger","year":"2009","unstructured":"Bensinger W, DiPersio JF, McCarty JM . Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant 2009; 43: 181\u2013195.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201679_CR41","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.3109\/10428194.2014.970544","volume":"56","author":"CS Sauter","year":"2015","unstructured":"Sauter CS, Giralt S . The prognostic impact of peripheral blood progenitor cell dose following high-dose therapy and autologous stem cell transplant for hematologic malignancies. Leuk Lymphoma 2015; 56: 1619\u20131625.","journal-title":"Leuk Lymphoma"},{"key":"BFbmt201679_CR42","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.bbmt.2014.05.003","volume":"20","author":"HK Duong","year":"2014","unstructured":"Duong HK, Savani BN, Copelan E, Devine S, Costa LJ, Wingard JR et al. Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2014; 20: 1262\u20131273.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201679_CR43","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.bbmt.2013.10.013","volume":"20","author":"S Giralt","year":"2014","unstructured":"Giralt S, Costa L, Schriber J, Dipersio J, Maziarz R, McCarty J et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transplant 2014; 20: 295\u2013308.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201679_CR44","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.transci.2013.02.034","volume":"48","author":"P Perseghin","year":"2013","unstructured":"Perseghin P, Marchetti M, Messina C, Mazzoni A, Carlier P, Perotti C et al. Best practice recommendations in: (1) Peripheral blood stem cell mobilization and collection and (2) acute and chronic GvHD treatment using extracorporeal photopheresis. A joint effort from SIdEM (Societ\u00e0 Italiana di Emaferesi e Manipolazione Cellulare) and GITMO (Gruppo Italiano Trapianto di Midollo Osseo). Transfus Apher Sci 2013; 48: 195\u2013196.","journal-title":"Transfus Apher Sci"},{"key":"BFbmt201679_CR45","first-page":"2103","volume":"32","author":"F Faussner","year":"2012","unstructured":"Faussner F, Dempke WC . Multiple myeloma: myeloablative therapy with autologous stem cell support versus chemotherapy: a meta-analysis. Anticancer Res 2012; 32: 2103\u20132109.","journal-title":"Anticancer Res"},{"key":"BFbmt201679_CR46","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/bmt.2012.173","volume":"48","author":"KE Armeson","year":"2013","unstructured":"Armeson KE, Hill EG, Costa LJ . Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: meta-analysis of trials with biological assignment. Bone Marrow Transplant 2013; 48: 562\u2013567.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201679_CR47","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1756-8722-6-2","volume":"6","author":"MA Kharfan-Dabaja","year":"2013","unstructured":"Kharfan-Dabaja MA, Hamadani M, Reljic T, Nishihori T, Bensinger W, Djulbegovic B et al. Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. J Hematol Oncol 2013; 6: 2.","journal-title":"J Hematol Oncol"},{"key":"BFbmt201679_CR48","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","volume":"376","author":"M Cavo","year":"2010","unstructured":"Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010; 376: 2075\u20132085.","journal-title":"Lancet"},{"key":"BFbmt201679_CR49","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1046\/j.1365-2141.2001.03033.x","volume":"114","author":"A Badros","year":"2001","unstructured":"Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 114: 822\u2013829.","journal-title":"Br J Haematol"},{"key":"BFbmt201679_CR50","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.bbmt.2010.02.020","volume":"16","author":"P Tosi","year":"2010","unstructured":"Tosi P, Zamagni E, Tacchetti P, Ceccolini M, Perrone G, Brioli A et al. Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency. Biol Blood Marrow Transplant 2010; 16: 1115\u20131121.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201679_CR51","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/bmt.2014.231","volume":"50","author":"C Girmenia","year":"2015","unstructured":"Girmenia C, Rossolini GM, Piciocchi A, Bertaina A, Pisapia G, Pastore D et al. Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: a nationwide retrospective survey from Italy. Bone Marrow Transplant 2015; 50: 282\u2013288.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201679_CR52","doi-asserted-by":"publisher","first-page":"e373","DOI":"10.3324\/haematol.2015.125484","volume":"100","author":"C Girmenia","year":"2015","unstructured":"Girmenia C, Viscoli C, Piciocchi A, Cudillo L, Botti S, Errico A et al. Management of carbapenem resistant klebsiella pneumoniae infections in stem cell transplant recipients: an italian multidisciplinary consensus statement. Haematologica 2015; 100: e373\u2013e376.","journal-title":"Haematologica"},{"key":"BFbmt201679_CR53","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1080\/10428190802535098","volume":"50","author":"A Anastasia","year":"2009","unstructured":"Anastasia A, Giglio F, Mazza R, Sarina B, Todisco E, Bramanti S et al. Early discharge after high-dose melphalan and peripheral blood stem cell reinfusion in patients with hematological and non-hematological disease. Leuk Lymphoma 2009; 50: 80\u201384.","journal-title":"Leuk Lymphoma"},{"key":"BFbmt201679_CR54","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/bmt.2009.254","volume":"44","author":"Center for International Blood and Marrow Transplant Research (CIBMTR), National Marrow Donor Program (NMDP), European Blood and Marrow Transplant Group (EBMT), American Society of Blood and Marrow Transplantation (ASBMT), Canadian Blood and Marrow Transplant Group (CBMTG), Infectious Disease Society of America (IDSA)","year":"2009","unstructured":"Center for International Blood and Marrow Transplant Research (CIBMTR), National Marrow Donor Program (NMDP), European Blood and Marrow Transplant Group (EBMT), American Society of Blood and Marrow Transplantation (ASBMT), Canadian Blood and Marrow Transplant Group (CBMTG), Infectious Disease Society of America (IDSA) et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Bone Marrow Transplant 2009; 44: 453\u2013558.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201679_CR55","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1007\/s00277-012-1456-8","volume":"91","author":"F Weissinger","year":"2012","unstructured":"Weissinger F, Auner HW, Bertz H, Buchheidt D, Cornely OA, Egerer G et al. Antimicrobial therapy of febrile complications after high-dose chemotherapy and autologous hematopoietic stem cell transplantation\u2014guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2012; 91: 1161\u20131174.","journal-title":"Ann Hematol"},{"key":"BFbmt201679_CR56","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1053\/j.gastro.2014.10.039","volume":"148","author":"KR Reddy","year":"2015","unstructured":"Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT, American Gastroenterological Association Institute. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015; 148: 215\u2013219.","journal-title":"Gastroenterology"},{"key":"BFbmt201679_CR57","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.bbmt.2012.08.016","volume":"19","author":"AM Bock","year":"2013","unstructured":"Bock AM, Cao Q, Ferrieri P, Young JA, Weisdorf DJ . Bacteremia in blood or marrow transplantation patients: clinical risk factors for infection and emerging antibiotic resistance. Biol Blood Marrow Transplant 2013; 19: 102\u2013108.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201679_CR58","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00277-013-1872-4","volume":"93","author":"JL Pi\u00f1ana","year":"2014","unstructured":"Pi\u00f1ana JL, Montesinos P, Martino R, Vazquez L, Rovira M, Lopez J et al. Incidence, risk factors, and outcome of bacteremia following autologous hematopoietic stem cell transplantation in 720 adult patients. Ann Hematol 2014; 93: 299\u2013307.","journal-title":"Ann Hematol"},{"key":"BFbmt201679_CR59","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1016\/j.bbmt.2015.06.017","volume":"21","author":"MJ Satlin","year":"2015","unstructured":"Satlin MJ, Vardhana S, Soave R, Shore TB, Mark TM, Jacobs SE et al. Impact of prophylactic levofloxacin on rates of bloodstream infection and fever in neutropenic patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2015; 21: 1808\u20131814.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"Suppl 6","key":"BFbmt201679_CR60","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/1469-0691.12464","volume":"20","author":"L Pagano","year":"2014","unstructured":"Pagano L, Caira M . The role of primary antifungal prophylaxis in patients with haematological malignancies. Clin Microbiol Infect 2014; 20 (Suppl 6): 19\u201326.","journal-title":"Clin Microbiol Infect"},{"key":"BFbmt201679_CR61","doi-asserted-by":"publisher","first-page":"S356","DOI":"10.1093\/cid\/ciu591","volume":"59","author":"DP Kontoyiannis","year":"2014","unstructured":"Kontoyiannis DP, Patterson TF . Diagnosis and treatment of invasive fungal infections in the cancer patient: recent progress and ongoing questions. Clin Infect Dis 2014; 59: S356\u2013S359.","journal-title":"Clin Infect Dis"},{"key":"BFbmt201679_CR62","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1200\/JCO.2012.45.8661","volume":"31","author":"CR Flowers","year":"2013","unstructured":"Flowers CR, Seidenfeld J, Bow EJ, Karten C, Gleason C, Hawley DK et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2013; 31: 794\u2013810.","journal-title":"J Clin Oncol"},{"key":"BFbmt201679_CR63","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/bmt.2012.257","volume":"48","author":"N Blijlevens","year":"2013","unstructured":"Blijlevens N, de Ch\u00e2teau M, Krivan G, Rabitsch W, Szomor A, Pytlik R et al. In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient's burden. Bone Marrow Transplant 2013; 48: 966\u2013971.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201679_CR64","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/bmt.2008.168","volume":"42","author":"P Tsirigotis","year":"2008","unstructured":"Tsirigotis P, Triantafyllou K, Girkas K, Giannopoulou V, Ioannidou E, Chondropoulos S et al. Keratinocyte growth factor is effective in the prevention of intestinal mucositis in patients with hematological malignancies treated with high-dose chemotherapy and autologous hematopoietic SCT: a video-capsule endoscopy study. Bone Marrow Transplant 2008; 42: 337\u2013343.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201679_CR65","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1093\/annonc\/mdq059","volume":"21","author":"G Kobbe","year":"2010","unstructured":"Kobbe G, Bruns I, Schroeder T, Czibere A, Warnecke J, Hieronimus N et al. A 3-\u2009day short course of palifermin before HDT reduces toxicity and need for supportive care after autologous blood stem-cell transplantation in patients with multiple myeloma. Ann Oncol 2010; 21: 1898\u20131904.","journal-title":"Ann Oncol"},{"key":"BFbmt201679_CR66","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1038\/bmt.2014.140","volume":"49","author":"G Milone","year":"2014","unstructured":"Milone G, Leotta S, Cupri A, Fauci AL, Spina P, Parisi M et al. Palifermin reduces infection rate and hyperfibrinogenemia in patients treated with high-dose chemotherapy based on beam or BU-thiothepa. Bone Marrow Transplant 2014; 49: 1193\u20131197.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201679_CR67","doi-asserted-by":"crossref","unstructured":"Worthington HV, Clarkson JE, Bryan G, Furness S, Glenny AM, Littlewood A et al. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev 2011; (4): CD000978.","DOI":"10.1002\/14651858.CD000978.pub4"},{"key":"BFbmt201679_CR68","first-page":"478","volume":"13","author":"S Bassi","year":"2015","unstructured":"Bassi S, Stroppa EM, Moroni CF, Arbasi MC, Trabacchi E, Di Franco A et al. Safety and efficacy of granulocyte colony-stimulating factor biosimilars in engraftment after autologous stem cell transplantation for haematological malignancies: a 4-year, single institute experience with different conditioning regimens. Blood Transfus 2015; 13: 478\u2013483.","journal-title":"Blood Transfus"},{"key":"BFbmt201679_CR69","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/j.jcyt.2015.05.010","volume":"17","author":"M Martino","year":"2015","unstructured":"Martino M, Recchia AG, Moscato T, Fedele R, Neri S, Gentile M et al. Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients. Cytotherapy 2015; 17: 1485\u20131493.","journal-title":"Cytotherapy"},{"key":"BFbmt201679_CR70","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/j.1600-0609.2006.00736.x","volume":"77","author":"M Martino","year":"2006","unstructured":"Martino M, Pratic\u00f2 G, Messina G, Irrera G, Massara E, Messina G et al. Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients. Eur J Haematol 2006; 77: 410\u2013415.","journal-title":"Eur J Haematol"},{"key":"BFbmt201679_CR71","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/j.1399-0012.2011.01532.x","volume":"26","author":"PD Ziakas","year":"2012","unstructured":"Ziakas PD, Kourbeti IS . Pegfilgrastim vs. filgrastim for supportive care after autologous stem cell transplantation: can we decide? Clin Transplant 2012; 26: 16\u201322.","journal-title":"Clin Transplant"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt201679.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt201679","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt201679.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T19:19:01Z","timestamp":1648063141000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt201679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,4]]},"references-count":71,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["BFbmt201679"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2016.79","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,4]]},"assertion":[{"value":"2 December 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}